PolyPid's drug-delivery tech combines polymers and lipids

PolyPid, an Israeli drug-delivery company, has introduced a new family of drug carriers based on a melding of two drug delivery systems: polymers and lipid-based systems. The PolyPid carrier carrier can be tailored to small molecules, peptides, protein and nucleic acids-based drugs.

The company's technology ensnares a large variety of one or more biologically active molecules and releases them at a pre-programmed rate for up to several months. PolyPid produces a product called BonyPid, a biodegradable bone void filler. After BonyPid releases its coating, over time, the bone void filler scaffold remains and supports bone recovery. This way, according to the company, physicians can "obtain the benefits of conventional bone void filler combined with an effective local drug delivery system."

"Due to its flexibility, the PolyPid platform can be utilized to address numerous medical indications in various fields, such as orthopedics, urology, periodontal, anti-cancer/anti-fungal treatments and surgical accessories," PolyPid CTO Noam Emanuel said in a news release.

- read PolyPid's release
- and a brief report on PBR

Webinar

Using AI and RWD to Uncover Rare Disease Insights, Accelerate Commercialization and Improve Patient Outcomes

Wednesday, March 24 | 2pm ET / 11am PT

Learn how IPM.ai transformed real world data into real world insights to assist Audentes in their development of AT132 for the treatment of XLMTM. The session reviews how IPM.ia and Audentes collaborated to uncover the XLMTM patient population.